Professor, Medicine, Tufts Medical Center
Hematology
Dr. Gary M. Strauss, MD
|
|
Give Review
Doctor Gary M. Strauss, MD practices Hematology. He researched medicine at Yale University School of Medicine. Yale University School of Medicine is a one of the best medicals schools. Yale University School of Medicine has a rank of 7 in research and a 57 in primary care He received 4 awards: "America's Top Doctors", "Boston Magazine", "America's Top Doctors for Cancer" and "Super Doctor". Dr. Gary M. Strauss is a published MD. He published 69 publications, including: 'The AtBCs of lung cancer screening.' He is registered with Medicare.
Publications
- Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung Cancer â¥4 cm in size: an SEER-Medicare analysis.
- Chest X-ray screening for lung Cancer: Overdiagnosis, endpoints, and randomized population trials.
- Outcomes After Adjuvant Platinum-based Chemotherapy in Elderly NSCLC Patients with T4 Disease.
- Induction Chemotherapy and Surgery for Early-Stage Non-Small-Cell Lung Cancer: What Have We Learned From Randomized Trials?
- Reproductive factors, hormone use, and risk for lung Cancer in postmenopausal women, the Nurses' Health Study.
- Adjuvant Gamma Knife radiosurgery following surgical resection of Brain metastases: a 9-year retrospective cohort study.
- Differences in clinical trial patient attributes and outcomes according to enrollment setting.
- Adjuvant vs neoadjuvant chemotherapy in resectable NSCLC: is that the real question?
- Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Thera...
- Management of early-stage lung Cancer: past, present, and future adjuvant trials.
- Como international conference position statement: lung Cancer screening for early diagnosis 5 years after the 1998 Varese conference.
- Adjuvant chemotherapy of lung Cancer: methodologic issues and therapeutic advances.
- The Mayo Lung Cohort: a regression analysis focusing on lung Cancer incidence and mortality.
- [Virtual endoscopy of the nose and paranasal sinuses in real-time. Surgical planning System "Sinus endoscopy" (SPS-SE)].
- The relationship between plasma viral load and neuropsychological functioning in HIV-1 infection.
- The role of second-look laparotomy in the long-term survival in ovarian Cancer.
- Clinical results in MR-guided therapy for malignant Gliomas.
- Cavernous malformations--navigational supported surgery.
- Treatment of advanced ovarian Cancer with sequential combination chemotherapy.
- Varese meeting report.
- Could chest X-ray screening for lung Cancer be cost-effective?
- Optimal therapy of malignant pleural effusions.
- Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.
- Phase II trial of high-dose cisplatin plus ifosfamide as first-line followed by carboplatin as second-line treatment in epithelial ovarian Carcinoma.
- Screening for lung Cancer: An evidence-based synthesis.
- Use of tumor markers in lung Cancer.
- Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung Cancer.
- Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective Analysis.
- Do race and ethnicity predict survival in metastatic non-small cell lung Cancer?
- Measuring effectiveness of lung Cancer screening: from consensus to controversy and back.
- Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression.
- Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
- The AtBCs of lung Cancer screening.
- Women and lung Cancer: waiting to exhale.
- Perception, paradox, paradigm: Alice in the wonderland of lung Cancer prevention and early detection.
- Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
- Screening for lung Cancer.
- Randomized population trials and screening for lung Cancer: breaking the cure barrier.
- Prognostic markers in resectable non-small cell lung Cancer.
- Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
- Gemcitabine and vinorelbine in patients with advanced lung Cancer: preclinical studies and report of a phase I trial.
- Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung Carcinoma.
- Lung Cancer screening and the surgical oncologist: the controversy.
- Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung Cancer (NSCLC).
- High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.
- Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung Cancer. Impact of preoperative chemotherapy on resectability and downstaging.
- Resection margins, extrapleural nodal status, and Cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: result...
- Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung Cancer.
- Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung Cancer.
- Advances in surgical staging and therapy of non-small-cell lung Cancer.
- Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma.
- An historical perspective of multi-modality treatment for resectable non-small cell lung Cancer.
- Extent of surgery and survival in early lung carcinoma: implications for overdiagnosis in stage IA nonsmall Cell lung carcinoma.
- A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung Cancer.
- Neoadjuvant and adjuvant therapy in the management of locally advanced non-small-cell lung Cancer.
- Role of chemotherapy in stages I to III non-small cell lung Cancer.
- Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung Cancer: update and preliminary survival analysis.
- Chest wall invasive non-small cell lung Cancer: patterns of failure and implications for a revised staging system.
- Screening for lung Cancer. Another look; a different view.
- Screening for lung Cancer re-examined. A reinterpretation of the Mayo Lung Project randomized trial on lung Cancer screening.
- Phase II study of topotecan in metastatic non-small-cell lung Cancer.
- Chest X-ray screening improves outcome in lung Cancer. A reappraisal of randomized trials on lung Cancer screening.
- Multimodality treatment of stage IIIA non-small-Cell lung carcinoma: a critical review of the literature and strategies for future research.
- Molecular and pathologic markers in stage I non-small-Cell carcinoma of the lung.
- Molecular pathologic substaging in 244 stage I non-small-cell lung Cancer patients: clinical implications.
- Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.
- Prognostic significance of mucin and p53 expression in stage IB non-small cell lung Cancer: a laboratory companion study to CALGB 9633.
- Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung Cancer: observational cohort study.
Schools
Yale University
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Great West Healthcare-Cigna PPO
- Commercial Insurance Company
- Fallon Community Health Plan
- First Health (Coventry Health Care) PPO
- Harvard Pilgrim Health Care PPO
- Medicare Advantage PFFS
- Humana
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Network Health
- Tufts Health Plans
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Boston Magazine
- America's Top Doctors for Cancer
- Super Doctor
Education
-
Massachusetts General Hospital -
Boston University Medical Center -
Yale University School of Medicine
Hospital
-
Tufts Medical Center
Drug Facts
| NPI NUMBER | 1447266036 | |
| NPPES Provider LastName | STRAUSS | |
| NPPES Provider FirstName | GARY | |
| NPPES Provider ZIPCode | 02903 | |
| NPPES Provider State | RI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 98.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1447266036 |
| Last Name Of The Provider | STRAUSS |
| First Name Of The Provider | GARY |
| View All |
Similar Doctors
|
|
Dr. Angelina C. Carvalho, MD |
|
|
Dr. Joseph A. Dibenedetto Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Todd F. Roberts, MD |
|
|
Dr. James M. Barbeau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Humera Khurshid, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert Black, MD |
|
|
Dr. Barbara E. Barker, PHD |
|
|
Dr. William Sikov, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raymond F. Chaquette, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rimini A. Varghese, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward G. Wittels, MD
This Doctor is OpenDoctor Recommended.
|